ES2513716T3 - Enzimas lecitina-colesteros acitransferasa modificadas - Google Patents

Enzimas lecitina-colesteros acitransferasa modificadas Download PDF

Info

Publication number
ES2513716T3
ES2513716T3 ES12003811.2T ES12003811T ES2513716T3 ES 2513716 T3 ES2513716 T3 ES 2513716T3 ES 12003811 T ES12003811 T ES 12003811T ES 2513716 T3 ES2513716 T3 ES 2513716T3
Authority
ES
Spain
Prior art keywords
cholesteros
acitransferase
enzymes
modified lecithin
lcat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12003811.2T
Other languages
English (en)
Inventor
Mingyue Zhou
Thomas Charles Boone
David Park Meininger
Margit Schwarz
Bei Shan
Wenyan Shen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ES2513716T3 publication Critical patent/ES2513716T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01043—Phosphatidylcholine-sterol O-acyltransferase (2.3.1.43), i.e. lecithin-cholesterol acyltransferase or LCAT

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)

Abstract

Polinucleotido que codifica una proteina lecitina-colesterol aciltransferasa (LCAT) modificada, en el que la proteina LCAT modificada comprende una modificacion en la secuencia de aminoacidos de LCAT madura expuesta en SEQ ID NO: 1 o SEQ ID NO: 2 tal como se expone en la figura 2, y la modificación consiste en una sustitucion en el residuo de aminoacido 031 seleccionada del grupo que consiste en C31I, C31M, 031F, 031V, C31W, C31Y, 031R y 031H.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31
imagen32
imagen33
imagen34

Claims (1)

  1. imagen1
ES12003811.2T 2007-07-26 2008-07-25 Enzimas lecitina-colesteros acitransferasa modificadas Active ES2513716T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95200707P 2007-07-26 2007-07-26
US952007P 2007-07-26

Publications (1)

Publication Number Publication Date
ES2513716T3 true ES2513716T3 (es) 2014-10-27

Family

ID=39864722

Family Applications (3)

Application Number Title Priority Date Filing Date
ES12003810.4T Active ES2559353T3 (es) 2007-07-26 2008-07-25 Enzimas lecitina-colesterol aciltransferasa modificadas
ES08796592T Active ES2449483T3 (es) 2007-07-26 2008-07-25 Enzimas lecitina-colesterol aciltransferasa modificadas
ES12003811.2T Active ES2513716T3 (es) 2007-07-26 2008-07-25 Enzimas lecitina-colesteros acitransferasa modificadas

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES12003810.4T Active ES2559353T3 (es) 2007-07-26 2008-07-25 Enzimas lecitina-colesterol aciltransferasa modificadas
ES08796592T Active ES2449483T3 (es) 2007-07-26 2008-07-25 Enzimas lecitina-colesterol aciltransferasa modificadas

Country Status (26)

Country Link
US (3) US8168416B2 (es)
EP (4) EP2489730B1 (es)
JP (5) JP5643643B2 (es)
KR (1) KR20100040937A (es)
CN (1) CN101855344B (es)
AU (1) AU2008279065B2 (es)
BR (1) BRPI0814310A2 (es)
CA (1) CA2694590A1 (es)
CR (1) CR11272A (es)
CY (2) CY1114857T1 (es)
DK (2) DK2181190T3 (es)
EA (1) EA201070187A1 (es)
ES (3) ES2559353T3 (es)
HK (1) HK1138039A1 (es)
HR (1) HRP20140315T1 (es)
IL (1) IL203399A0 (es)
MX (1) MX348799B (es)
MY (1) MY159075A (es)
NZ (2) NZ582794A (es)
PL (2) PL2489731T3 (es)
PT (2) PT2181190E (es)
RS (1) RS53237B (es)
SG (1) SG186016A1 (es)
SI (2) SI2489731T1 (es)
UA (1) UA103304C2 (es)
WO (1) WO2009015314A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ582794A (en) * 2007-07-26 2012-09-28 Amgen Inc Modified lecithin-cholesterol acyltransferase enzymes
NZ596639A (en) * 2009-06-12 2014-02-28 Alphacore Pharma Llc Use of lcat for treating anemia and red blood cell dysfunction
CN103025348B (zh) 2010-05-06 2015-09-02 阿尔法科制药有限责任公司 传递类固醇到胆甾醇酯合成组织
WO2012114131A1 (en) * 2011-02-25 2012-08-30 University Of Patras Lecithin:cholesterol acyltransferase (lcat) and its role in nonalcoholic fatty liver disease (nafld)
CA2833931C (en) * 2011-05-05 2021-05-04 Wellstat Immunotherapeutics, Llc Complement factor b analogs and their uses
AU2012347540A1 (en) 2011-12-08 2014-06-26 Amgen Inc. Agonistic human LCAT antigen binding proteins and their use in therapy
US20180265885A1 (en) * 2015-01-29 2018-09-20 Plantvax, Inc. Highly expressed protective plant-derived broadly neutralizing hiv monoclonal antibodies for use in passive immunotherapy
US11883470B2 (en) 2016-07-25 2024-01-30 The Trustees Of The University Of Pennsylvania Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
KR20200085292A (ko) * 2017-11-07 2020-07-14 알파코어 파마 엘엘씨 심장 질병, 심혈관 질병 및 관련 질환 및 증상을 치료하고 그로부터 보호하는 방법
US20210115412A1 (en) * 2018-05-22 2021-04-22 Dsm Ip Assets B.V. Modified sterol acyltransferases
US11612619B2 (en) 2018-11-01 2023-03-28 National Institute Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Compostions and methods for enabling cholesterol catabolism in human cells
KR200493485Y1 (ko) * 2019-08-27 2021-04-07 주식회사 서원기술 배관용 고무링

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
JPS63167409A (ja) 1986-12-27 1988-07-11 Yamaha Corp 磁気記録体
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
CH671155A5 (es) 1986-08-18 1989-08-15 Clinical Technologies Ass
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US6288095B1 (en) 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
ATE186724T1 (de) 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
DE3889853D1 (de) 1987-11-05 1994-07-07 Hybritech Inc Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik.
GB8824591D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA2082951C (en) 1991-03-15 1999-12-21 Robert M. Platz Pulmonary administration of granulocyte colony stimulating factor
HU217629B (hu) 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
ATE156158T1 (de) 1992-04-14 1997-08-15 Cornell Res Foundation Inc Makromoleküle auf basis von dendritischen polymeren und verfahren zur herstellung
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5741803A (en) 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
ES2133158T3 (es) 1993-01-19 1999-09-01 Warner Lambert Co Formulacion ci-981 oral, estable y proceso de preparacion del mismo.
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
CZ294108B6 (cs) 1995-07-17 2004-10-13 Warner@Lambertácompany Krystalická forma I hydrátu atorvastatinuŹ tj@ semivápenaté soli kyseliny [R@}RgŹRgB]@}@fluorfenylB@betaŹdelta@dihydroxy@Q@}�@methylethylB@fenyl[}fenylaminoBkarbonyl]@�H@pyrrol@�@heptanové
US6635614B1 (en) * 1995-11-09 2003-10-21 The United States Of America As Represented By The Department Of Health And Human Services Use of lecithin-cholesterol acyltransferase (LCAT) to reduce accumulation of cholesterol
DE69731289D1 (de) 1996-03-18 2004-11-25 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
FR2758459B1 (fr) 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US6498019B1 (en) * 1997-04-11 2002-12-24 Takeda Chemical Industries, Ltd. Lecithin-cholesterol acyltransferase protein
DE69818444T2 (de) 1998-07-15 2004-05-06 Merck Santé Tabletten enthaltend eine Kombination von Glibenclamid und Metformin
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
WO2001005943A2 (en) 1999-07-14 2001-01-25 Betagene, Inc. Lcat recombinant cell line compositions and methods
ATE540681T1 (de) 2006-06-26 2012-01-15 Amgen Inc Verfahren zur behandlung von atherosklerose
NZ582794A (en) * 2007-07-26 2012-09-28 Amgen Inc Modified lecithin-cholesterol acyltransferase enzymes

Also Published As

Publication number Publication date
EA201070187A1 (ru) 2010-08-30
NZ582794A (en) 2012-09-28
HRP20140315T1 (hr) 2014-05-09
NZ597885A (en) 2013-08-30
EP2181190B1 (en) 2014-01-08
CR11272A (es) 2010-05-26
EP2522721B1 (en) 2016-05-04
AU2008279065A1 (en) 2009-01-29
WO2009015314A3 (en) 2009-03-12
EP2489731A1 (en) 2012-08-22
WO2009015314A2 (en) 2009-01-29
PT2489731E (pt) 2014-09-15
JP2014198047A (ja) 2014-10-23
US20090081182A1 (en) 2009-03-26
PL2489731T3 (pl) 2015-01-30
PL2181190T3 (pl) 2014-06-30
ES2559353T3 (es) 2016-02-11
SG186016A1 (en) 2012-12-28
EP2489731B1 (en) 2014-08-27
DK2489731T3 (en) 2014-11-17
AU2008279065B2 (en) 2013-12-12
JP2016182136A (ja) 2016-10-20
JP2020058366A (ja) 2020-04-16
CN101855344A (zh) 2010-10-06
KR20100040937A (ko) 2010-04-21
US9006408B2 (en) 2015-04-14
EP2489730A1 (en) 2012-08-22
JP2018161134A (ja) 2018-10-18
CA2694590A1 (en) 2009-01-29
MY159075A (en) 2016-12-15
CN101855344B (zh) 2015-12-09
UA103304C2 (ru) 2013-10-10
HK1138039A1 (en) 2010-08-13
BRPI0814310A2 (pt) 2015-01-06
EP2522721A2 (en) 2012-11-14
PT2181190E (pt) 2014-02-24
EP2489730B1 (en) 2015-12-30
DK2181190T3 (da) 2014-03-31
JP5643643B2 (ja) 2014-12-17
RS53237B (en) 2014-08-29
EP2181190A2 (en) 2010-05-05
CY1115573T1 (el) 2017-01-04
MX348799B (es) 2017-06-29
EP2522721A3 (en) 2013-01-23
ES2449483T3 (es) 2014-03-19
CY1114857T1 (el) 2016-12-14
US8168416B2 (en) 2012-05-01
SI2181190T1 (sl) 2014-04-30
IL203399A0 (en) 2011-07-31
US20140287479A1 (en) 2014-09-25
JP6033258B2 (ja) 2016-11-30
JP2010534479A (ja) 2010-11-11
SI2489731T1 (sl) 2014-12-31
US8703926B1 (en) 2014-04-22

Similar Documents

Publication Publication Date Title
ES2513716T3 (es) Enzimas lecitina-colesteros acitransferasa modificadas
ES2481040T3 (es) Oligonucleótidos inmunoestimulantes
ES2616658T3 (es) Péptidos que mimetizan el factor de crecimiento y sus usos
ES2572955T3 (es) Composiciones y usos para el tratamiento de la proteinosis alveolar pulmonar
ES2568803T3 (es) Reducción del contenido de ácidos grasos saturados en semillas de plantas
ES2545457T3 (es) Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1
CL2013003416A1 (es) Secuencia de peptidos quiméricos que comprende dsspl o dasph composiciones , usos y metodo para mejorar metabolismo de glucosa.
AR049177A1 (es) Polipeptidos y conjugados de interferon-alfa
DK2014678T3 (da) KDR-peptider og vacciner indeholdende disse
ES2691070T3 (es) Péptidos antiinflamatorios y composición que comprende los mismos
EA200901430A1 (ru) Варианты фермента аспарагиназы и их применение
IL226857A (en) Recombinant proteins that underwent glycosylation at site n correspond to prokaryotes
PE20220960A1 (es) Proteinas de variantes de secuencias de aminoacidos de cry1da1 activas para lepidopteros
WO2009024327A3 (en) New proteins for use in human and animal staphylococcus infections
WO2008040190A8 (en) Small peptides for anti-angiogenesis and use thereof
ES2562919T3 (es) Proteína y secuencia de ADN que codifica una actividad del tipo de la subtilisina adaptada al frío
ES2609586T3 (es) Secuencias de nucleótidos y aminoácidos que codifican una proteína exportada 1 derivada de Plasmodium vivax y usos de las mismas
WO2016036635A8 (en) Chromobacterium subtsugae genes
AR047590A1 (es) Alteracion de la estructura de la raiz durante el desarrollo de la planta
ES2633468T3 (es) Agente inductor de inmunidad y método para la detección del cáncer
MX2010010177A (es) Fragmentos de beta timosina mejorada.
ES2560329T3 (es) Procedimiento de transformación de iota-carragenano en alfa-carragenano por medio de una clase novedosa de 4S-iota-carragenano sulfatasa
MX2016002556A (es) Métodos y composiciones para el tratamiento de patologías del tejido de cartílago y disco.
ES2545458T3 (es) Fragmentos de PTEC
GB0818080D0 (en) Immunogenic peptides